

1 **Geranylgeraniol supplementation leads to an improvement in inflammatory parameters**
2 **and reversal of the disease specific protein signature in patients with hyper-IgD**
3 **syndrome**

4
5 Anna Sediva¹, Martin Orlicky¹, Petra Vrabцова¹, Adam Klocperk¹, Tomas Kalina², Hideji
6 Fujiwara³, Fong-Fu Hsu³, Monika Bambouskova^{3,*}

7
8 ¹Department of Immunology, Second Faculty of Medicine, Charles University and Motol
9 University Hospital, Prague, Czech Republic

10 ²Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles
11 University and Motol University Hospital, Prague, Czech Republic

12 ³Division of Endocrinology, Metabolism & Lipid Research, Washington University School of
13 Medicine, St. Louis, MO, 63110, USA.

14
15 *Correspondence: monika.bambouskova@wustl.edu

16
17 **Abstract**

18 Mevalonate kinase (MVK) deficiency, a rare autosomal recessive disease, significantly impacts
19 metabolism and immunity, leading to mevalonic aciduria in severe cases and hyper-IgD
20 syndrome (HIDS) in partial deficiency. These conditions arise due to disruptions in the
21 mevalonate pathway, which is essential metabolic pathway responsible for the synthesis of
22 non-sterol isoprenoids and other molecules. The resulting metabolic blockade triggers
23 autoinflammatory responses, primarily due to deficient isoprenoid intermediates such as
24 geranylgeranyl pyrophosphate (GGPP). This first reported pilot study evaluates the safety and
25 efficacy of dietary geranylgeraniol supplementation (GG) in three patients with HIDS. Over
26 three months, GG supplementation showed no liver toxicity and did not alter lipid profiles.
27 Although GG did not rise the plasma levels of GGPP, the plasma proteomics showed
28 significant changes induced by GG. Proteomic analysis further revealed that GG
29 supplementation can reverse some of the features of HIDS-specific plasma protein signature,
30 highlighting its potential to modulate inflammation and protein prenylation pathways. These
31 findings suggest that GG supplementation could be a promising metabolic intervention to
32 mitigate inflammation in HIDS, warranting further, more targeted investigation in larger clinical
33 trials.

34
35 **Key words:** immunometabolism, mevalonate pathway, HIDS, rare disease, autoinflammation

36 Introduction

37 Mevalonate kinase (MVK) deficiency is a rare autosomal recessive disease that falls
38 into the area of inborn errors of metabolism, but also into inborn errors of immunity due to the
39 consequences the metabolic defect exerts on the immune system. A profound MVK deficiency
40 manifests with mevalonic aciduria, a severe condition characterized by inflammatory episodes,
41 syndromic and neurological impairments, and psychomotor retardation. In contrast, milder
42 deficiency with partially preserved MVK function leads to hyper-IgD syndrome (HIDS). The
43 metabolic disturbance is a direct consequence of blockade in the mevalonate pathway, which
44 is crucial for production of isoprenoids and sterols that are key for synthesis of various
45 biologically significant molecules including cholesterol, dolichol, and ubiquinone. The
46 immunological consequences of MVK deficiency manifest as an autoinflammatory disease
47 accompanied by recurrent febrile episodes and elevated serum IgD levels, a common, albeit
48 inconsistent marker from which HIDS gets its name^{1,2}.

49 The autoinflammatory state associated with MVK deficiency is linked to isoprenoid
50 deficiency due to the blockage in the metabolic pathway. Isoprenoids are essential for protein
51 prenylation, a post-translational modification attaching 15-carbon (farnesyl) or a 20-carbon
52 (geranylgeranyl) isoprenoid lipid to the Cys residue by specific transferases. Large group of
53 proteins regulated by prenylation are small GTPases such as Ras, Rab, Rho and others³.
54 Attached prenyl groups can regulate cellular localization and function of the proteins and
55 prenylation was found to be defective in patients with HIDS⁴.

56 The inflammatory manifestations in HIDS are primarily mediated by inflammasome
57 activation, which likely occurs through several distinct mechanisms. The deficiency of
58 isoprenoids, particularly geranylgeranyl pyrophosphate (GGPP), leads to inactivation of RhoA
59 GTPase, which subsequently triggers the pyrin inflammasome^{2,5,6,7}. Additionally, defective
60 protein prenylation, particularly in small GTPases, also activates the NLRP3 inflammasome in
61 monocytes⁸. These findings suggest that both pyrin and NLRP3 inflammasomes participate in
62 inflammation induced by MVK dysfunction, with isoprenoid deficiency serving as a crucial
63 trigger of these inflammatory processes.

64 The accumulation of mevalonate upstream of the metabolic block in the mevalonate
65 pathway may also contribute to the condition. The mevalonate buildup in monocytes from
66 patients with HIDS resulted in their inflammatory state and a phenomenon known as "trained
67 immunity". This associates with an enhanced non-specific inflammatory immune response,
68 which can further contribute to inflammation in the context of MVK deficiency⁹.

69 Apart from its complex effects on innate immunity, MVK deficiency, primarily through
70 reduction of isoprenoids such as GGPP, also influences adaptive immunity. A recent study
71 highlights significant role of GGPP in B lymphocytes connected to the defective IL-10 secretion
72 in patients with MVK deficiency. Therefore, reduced B cell-derived anti-inflammatory IL-10

73 production may be a contributing factor to the inflammatory phenotype in HIDS¹⁰. Furthermore,
74 mevalonate metabolism and protein prenylation were also shown to be involved in the
75 regulation of T cell homeostasis; in this context protein geranylgeranylation exhibits unique
76 role in enabling thymic egress, while farnesylation is more involved in the regulation of
77 peripreral T cell homeostasis¹¹.

78 Another intriguing aspect of the MVK deficiency is the elevated level of IgD, which gives
79 rise to the name "hyper-IgD syndrome." Although the increase of IgD is also observed in other
80 autoinflammatory diseases, it is most pronounced in HIDS. The mechanism behind the
81 elevated IgD levels remains unclear. Recent studies suggest that the increase in IgD may be
82 an independent phenomenon, possibly not directly responsible for the inflammation¹². IgD,
83 along with IgM, serves as a membrane receptor involved in B lymphocyte development and
84 activation. IgD and IgM are expressed on B lymphocytes in specifically arranged membrane
85 islands with a distinct nanostructure¹³. A recently published hypothesis provides a new
86 perspective on the potential cause of elevated IgD, linking it to a reduction in signaling through
87 membrane IgM. Unlike signaling through IgD, signaling through IgM requires MAPK activation
88 which depends on protein prenylation^{14,15}. According to this hypothesis, the increased IgD level
89 in MVK deficiency is a result of disrupted balance in IgM/IgD expression and signaling on B
90 lymphocytes due to impaired MAPK pathway. This signaling imbalance is caused by impaired
91 prenylation of components in the MAPK signaling cascade, particularly Ras¹⁴.

92 While this hypothesis remains to be fully validated, shortage of isoprenoids leading to
93 impaired protein prenylation due to the mevalonate pathway blockade has been repeatedly
94 demonstrated and recognized as a crucial factor in the inflammatory manifestations of the MVK
95 deficiency. The rationale for supplementing isoprenoids to restore protein prenylation is
96 supported by numerous *in vitro* and *in vivo* studies. Specifically, GGPP or its derivative
97 geranylgeraniol, was shown to restore prenylation-associated defects in cells with dysfunctional
98 MVK^{8,10,16} and reduced inflammation in mouse model of chemically induced MVK deficiency¹⁷.
99 This strategy is consistently highlighted in publications as a plausible approach to rectify the
100 metabolic defect caused by MVK dysfunction, however its potential to treat HIDS in human
101 has not yet been tested.

102 In light of the aforementioned evidence, we conducted a pilot study evaluating the
103 effects of dietary supplementation of geranylgeraniol in a small group of patients with MVK
104 deficiency presenting with HIDS.

105

106 **Patients and methods**

107 *The pilot study*

108 In the pilot study, we aimed to verify the safety and efficacy of the dietary supplementation of
109 geranylgeraniol in three patients with MVK deficiency/HIDS. The study was approved by the

110 Ethical Committee, Motol University Hospital, Prague, Ref. Number EK 30/22, and by the
111 Czech Agriculture and Food Inspection Authority who oversees the field of food supplements.
112 All patients signed informed consent with the study.

113

114 *Dietary supplementation*

115 Geranylgeraniol in a form of dietary supplement GG Pure (Extendlife Natural Products)
116 containing GG gold®30 Annatto Extract, 500 mg capsule (30% geranylgeraniol, 150 mg per
117 capsule) was administered once daily for 3 months.

118

119 *Patients*

120 A total of three patients were involved in the study, two females and one male, age of 20-30,
121 and 50-60. All patients were compound heterozygotes for mutations in MVK. We included
122 patients who are followed in Motol hospital and are coming for regular visits. Inclusion criteria
123 required the subjects to be above 12 years old, confirmed diagnosis of HIDS and compliance
124 with the study. Patients were treated with NSAIDs and Anakinra on demand at the time of the
125 attack. Patient 1 used Anakinra only for more severe attacks. She started the study and used
126 GG supplementation for 6 weeks when she experienced an allergic reaction to a combination
127 of non-steroid anti-inflammatory drugs taken together with GG supplement. Subsequent
128 investigation failed to prove the causality of the reaction, but the patient stopped the
129 supplement during the rest of the pilot period. Patient 2 applied Anakinra regularly every 1-2
130 days and was on maintenance corticosteroid therapy (Prednisone 10 mg every other day) in
131 addition to GG supplementation. Patient 3 used GG supplementation throughout the study and
132 did not apply Anakinra during the study period. At the time of sampling, all patients were in a
133 quiet period, away from inflammatory attacks, without acute inflammatory symptoms. Statin
134 group consisted of three controls, two females aged 50-60 and one male 40-50 years, all were
135 using Atorvastatin at a dose of 10 mg/day.

136

137 **Plasma and serum collection**

138 Blood was collected into ethylenediaminetetraacetic acid (EDTA) tubes at room temperature
139 and centrifuged at 3000 rpm for 5 minutes. Plasma was immediately frozen at -80°C and
140 stored until profiling. Serum was similarly obtained from a routine collection of coagulable
141 blood.

142

143 **Liver function assessment/enzyme assays**

144 Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were assessed by the
145 routine colorimetric IFCC methods in serum. Bilirubin levels in serum were measured by
146 vanadate oxidase method.

147

148 **Lipid measurements**

149 Lipid profile in serum consisting of total cholesterol, HDL-cholesterol (HDL), LDL-cholesterol
150 (LDL) and triglycerides (TAG). Lipids were measured by routine methods using enzyme
151 CHOD-PAP end point test (Enzymatic Colorimetric Determination in sera).

152

153 **Flow cytometry measurements**

154 Flow cytometry for B panel analysis was performed from isolated PMBCs, using the following
155 panel of antibodies - dried mixture of IgD FITC, CD27 PE, CD24 PerCP-Cy5.5, CD19 PE-Cy7,
156 CD21 APC, and CD38 APC-Cy7 (Custom-design dry reagent tube, Exbio Praha, Vestec,
157 Czech Republic) that allowed to determine subsets of B cells defined as naïve, MZ-like,
158 switched memory B cells and plasmablasts (see Fig. S2 for gating strategy).

159

160 **Analysis of isoprenoid pyrophosphates in plasma**

161 *LC-MS/MS analysis*

162 Negative-ion electrospray ionization (ESI) LC-MS/MS analysis of isoprenoid pyrophosphates
163 (GPP, FPP, and GGPP) in plasma and added $^{15}\text{N}_5$ -ADP internal standard was conducted on
164 an ABI-4000 QTRAP triple stage mass spectrometer, coupled to a Shimadzu 20 ADX HPLC
165 system with a SIL-20AC autosampler. To separate the three analytes and the internal
166 standard, a Waters Atlantis dC18 HPLC column (4.6 x 150 mm, 100 Å, 3 µm) was used for a
167 linear gradient separation starting with 40% mobile phase A (5 mM NaHCO_3 in water) to 100
168 % mobile phase B (1% NH_4OH in 1:1 Methanol/acetonitrile) in 5 min at the flow rate 1.0
169 ml/min. Multiple reaction monitoring (MRM) was used for detection of GPP (313.1 → 79.0),
170 FPP (381.1 → 79.0), GGPP (449.2 → 79.0), and $^{15}\text{N}_5$ -ADP standard (431.0 → 79.0). An
171 aliquot of 5 µL of each sample as prepared below was injected and analyzed twice. The
172 resultant data from two injections were averaged.

173

174 *Sample preparation*

175 To prepare samples for MRM LC-MS/MS analysis, plasma samples (200 µL each in an
176 Eppendorf tube) were added 800 µL of methanol containing 2 µg of $^{15}\text{N}_5$ adenosine
177 diphosphate (ADP) as an internal standard. The samples were vortexed, and centrifuged to
178 precipitate the protein. The supernatant was transferred to a new vial, dried under a stream
179 of nitrogen at room temperature, and reconstituted in 100 µL methanol. A set of four-point
180 calibration samples with 1 ng, 5 ng, 10 ng, and 20 ng of each analyte in 900 µL with the
181 same amount of the internal standard were also prepared to establish a linear calibration
182 curve for absolute quantification of the three analytes.

183

184

185 **Plasma proteomic profiling by SomaScan 7K assay**

186 For each sample, 500 μ L of frozen plasma was shipped on dry ice to the Genome Technology
187 Access Center (GTAC) core facility at Washington University in St. Louis for high-density
188 protein expression analysis via SomaScan assay¹⁸ (somalogic). Profiles of 7290 analytes were
189 acquired. Pre-processing was performed by GTAC core facility at Washington University in St.
190 Louis: raw relative fluorescence units measurements for every SOMAmer reagent were
191 normalized subsequently with hybridization normalization, plate scaling, median scaling and
192 calibrator normalization and transformed in \log_2 scale. Subsequently, differential analysis was
193 performed using limma statistics implemented in web-based platform Phantasus version:
194 1.21.5¹⁹. The probes recognizing the same analytes were not collapsed as they can recognize
195 different activation states of the same proteins, or different domains/subunits of the same
196 proteins (further specified in SomaScan assay annotation **Supplementary Table 1**). Gene set
197 enrichment analysis (GSEA) was performed on proteins ranked by limma statistics. To
198 determine enriched pathways either all differentially detected proteins were used or 200 most
199 upregulated and 200 most downregulated proteins were used in MSigDB CP: canonical
200 pathways and H: hallmark gene sets collections.

201

202 **Targeted detection of proteins**

203 Proteins in plasma were determined by ELISA using following kits: Human Proteinase 3
204 (PRTN3) ELISA, (BioVendor, #RAI001R, Czech Republic); LEGEND MAX™ Human
205 Myeloperoxidase ELISA Kit (Biolegend, #440007 USA) as recommended by manufacturer's
206 protocols. Proteins in serum: serum amyloid A (SAA), C-reactive protein (CRP) and IgD were
207 analyzed by routine laboratory methods, SAA by immunoturbidimetry, CRP and IgD by
208 nephelometry.

209

210 **Statistical analysis**

211 If not stated otherwise data represents mean \pm SEM from N samples as indicated. *P* values
212 were determined using statistical methods described in figure legends using GraphPad Prism
213 v10.0.2, statistical significance was defined as $p < 0.05$.

214

215 **Results**

216 **Study design and rationale**

217 Key metabolites synthesized through mevalonate pathway include non-sterol isoprenoids,
218 which are crucial for protein prenylation such as farnesylation and geranylgeranylation (**Fig.**
219 **1A**). The defective protein prenylation, presumably due to the shortage in isoprenoid
220 intermediates, has been observed in monocytes from patients with MVK deficiency and

221 connected to inflammation in HIDS²⁰. We aimed to test efficacy and safety of supplementation
222 of isoprenoid end product (**Fig. 1B**), geranylgeraniol (GG; Gold®30 Annatto Extract 500 mg,
223 30% geranylgeraniol, 150 mg), administered for 3 months (**Fig. 1C**). The plasma and PBMC
224 from HIDS patients were collected before and after 3 months of the treatment. To determine
225 safety of the treatment, additional samples were collected at 1 month of the treatment for
226 routine investigation of blood counts and hepatic function. We also included a control group of
227 healthy donors and group of donors using statins to compare HIDS condition with
228 pharmacologically inhibited mevalonate pathway (**Fig. 1D**). Three patients with HIDS were
229 enrolled in pilot study (two females and one male, aged 20-30 and 50-60, all compound
230 heterozygotes for mutations in MVK). Patients were treated with NSAIDs and Anakinra on
231 demand at the time of attack; the patient 2 applied Anakinra regularly every 1-2 days and was
232 on maintenance corticosteroid therapy, in addition to GG supplementation (**Fig. 1E, F**). The
233 subjective clinical status was followed by questionnaire with 6 relevant parameters – overall
234 feeling, temperature, fatigue, skin presentation, headache and abdominal pain, the objective
235 clinical presentation was checked during entry and follow-up visits by physicians. Despite
236 detailed instructions on monitoring their clinical status, the patients did not fill in the
237 questionnaires consistently. The results are therefore inconclusive, but showed stabilization to
238 slight improvement, most notably in general fatigue. All patients took the dietary supplement
239 at the recommended dose of one capsule per day (150 mg of geranylgeraniol), without
240 significant side effects with exception of one patient with a suspected allergic reaction at the
241 second month of use, which was more likely to the concomitant non-steroidal anti-inflammatory
242 drugs and mild, short, and self-limiting muscle pain reported by another patient.

243

244 **GG supplementation does not induce liver toxicity, nor does it alter lipid composition** 245 **and isoprenoid pyrophosphate levels in plasma**

246 To evaluate the effect of the GG supplementation on liver functions we assessed activity of
247 aspartate transaminase (AST), alanine transaminase (ALT) and serum levels of bilirubin. The
248 normal values of these parameters are 0.16-0.72 $\mu\text{kat/L}$ for AST, 0.17-0.78 $\mu\text{kat/L}$ for ALT and
249 5.0-21.0 $\mu\text{mol/L}$ for bilirubin. At any timepoint of the GG supplementation the values did not
250 exceed the limits, except minor increase in patient 2 in AST at 1 month of supplementation that
251 normalized at month 3 (**Fig. 2A**). To evaluate the impact of GG supplementation on lipid
252 metabolism, we analyzed cholesterol, high-density lipoprotein (HDL), and low-density
253 lipoprotein (LDL) levels in patient plasma at baseline (time 0), as well as after 1 and 3 months
254 of GG supplementation. No significant differences in any of these assessed parameters were
255 found following GG supplementation (**Fig. 2B**). This data indicates that GG used in a given
256 dose does not interfere with cholesterol and lipid transport pathways in HIDS patients. Next,
257 the rationale behind GG supplementation lies in its potential to replenish geranylgeranyl

258 moieties possibly depleted due to the MVK deficiency. To investigate whether GG can
259 contribute to the plasma pool of isoprenoid pyrophosphates, we examined the plasma levels
260 of geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl
261 pyrophosphate (GGPP) using targeted LC-MS/MS analysis. Among the tested isoprenoid
262 intermediates, only GGPP exhibited a significant decrease in HIDS patients compared to
263 controls (**Fig. 2C, Fig. S1**). As anticipated, GGPP levels were notably reduced also in the statin
264 group, indicating that GGPP is the intermediate most susceptible to depletion in the settings
265 of MVK pathway inhibition. However, supplementation with GG did not result in increase in
266 GGPP levels suggesting that geranylgeraniol may not be readily metabolized to
267 pyrophosphate in the circulation or undergoes metabolic turnover that precludes its detection
268 in the plasma at this dose.

269

270 **Phenotyping of B lymphocytes**

271 The B lymphocytes were determined as CD19⁺ cells in peripheral blood mononuclear cells
272 (PBMCs) from all experimental groups. The absolute B cell counts were normal in all samples,
273 ranging from 0,04 to 0,15 (normal values 0,03-0,40 x 10⁹/L) and the total counts did not change
274 after GG supplementation (data not shown). In addition, subpopulations of B lymphocytes
275 defined as naïve, MZ like lymphocytes, memory, switched memory and plasmablasts were
276 detected using the B cell panel (as described in *Methods* section). The samples post-treatment
277 with GG trended towards increased CD19⁺ B cells and decreased plasmablasts in patients
278 whose initial plasmablast counts were higher than in controls (**Fig. 3, Fig. S2**). However, the
279 results are strongly influenced by the small number of patients and also by the lack of initial B
280 panel determination in patient 2. This trend needs to be verified in a targeted follow-up in a
281 larger cohort of patients with MVK deficiency.

282

283 **GG supplement reverses HIDS-specific plasma protein signature**

284 To examine global proteomic alterations in patient plasma, we utilized SomaScan 7K assay,
285 identifying approximately 7290 analytes. Plasma from all experimental groups (**Fig. 1D**) was
286 analyzed in one run. Principal component analysis (PCA) based on all detected analytes
287 showed separation between healthy control donors and samples from HIDS patients,
288 indicating a unique plasma protein profile associated with HIDS (**Fig. 4A**). Statin group was
289 less separated from healthy control group and further distinguished from HIDS. GG
290 supplementation induced alteration in the plasma protein composition in HIDS but did not lead
291 to normalization of the global protein profile. We aimed to utilize this unique rare disease
292 dataset to get an insight into specific plasma changes associated with HIDS. Although the
293 plasma from HIDS patient show altered protein composition, individual gene differences did
294 not reach statistical significance due to limited sample size and inclusion of patient with clearly

295 different inflammatory status (patient 2) resulting from her intensive and continuous anti-
296 inflammatory therapy consisting of IL-1 blockade and corticosteroids (**Fig. 4B, Fig. S3A, B**).
297 Since pathway analysis provides a broader biological context by uncovering coordinated
298 changes in groups of genes/proteins, we performed pathway analysis focusing on the
299 upregulated and downregulated proteins detected in HIDS plasma compared to healthy
300 controls. The analysis revealed an associations with critical processes including post-
301 translational modification, innate immune response, cytokine signaling, and
302 geranylgeranylation (**Fig. 4C Fig. S3C**). Among downregulated pathways we found pathways
303 connected to signaling and extracellular matrix organization. Statin group at this size did not
304 show extensive difference when compared with healthy control group, however, pathway
305 analysis suggested enrichment in Rho signaling indicating potential intersection of the
306 processes involved in MVK block by statins and dysfunction in HIDS patients involving small
307 GTPases (**Fig. S3D, E**). These findings align with anticipated inflammatory status of the HIDS
308 patients and abnormalities likely stemming from the deficiency of isoprenoids.

309 Next we focused on differences in HIDS plasma induced by GG. We found 140 proteins
310 significantly altered by GG supplementation (137 up a 3 down; **Fig. 4D**). Pathway enrichment
311 analysis highlighted processes centering around Rho GTPase signaling, tyrosine kinase
312 receptor signaling, and membrane trafficking upon GG treatment (**Fig. 4E, F**). This suggested
313 a potential interference of GG supplement with protein prenylation-associated signaling. The
314 most upregulated proteins were specifically up in GG-treated group and reached up to 3 log₂
315 difference in intensity units compared to healthy donors (**Fig. S4A**). To investigate whether GG
316 has a potential to modulate the characteristic protein profile of HIDS patient plasma, we ranked
317 proteins based on the comparison between controls and HIDS samples and performed Gene
318 Set Enrichment Analysis (GSEA) using proteins regulated by GG. The GSEA analysis
319 indicated a statistically significant overlap between proteins elevated in HIDS and proteins
320 downregulated by GG, as well as proteins decreased in HIDS and upregulated by GG (**Fig.**
321 **4G, Fig. S4B**). Similarly, when proteins were ranked based on comparison between HIDS and
322 HIDS + GG groups, GSEA showed significant overlap with HIDS disease signature (**Fig. S4C**).
323 These results suggests that GG supplementation has potential to revert key features of HIDS
324 protein signature in patient plasma.

325 To experimentally validate changes in inflammatory signature of HIDS patients upon
326 GG treatment we aimed to use the proteomics dataset to find suitable markers. For this
327 purpose, we compared healthy controls with HIDS patients including only patient 1 and 3,
328 excluding patient 2 who was treated by consistent corticosteroid treatment (**Fig. 4H**). We
329 selected several protein targets that showed downregulation/normalization by GG and
330 validated their expression by targeted standard laboratory tests/ELISA assays. The following
331 proteins were evaluated: Serum amyloid A (SAA), Myeloperoxidase (MPO) and Proteinase 3

332 (also Myeloblastin; PRTN3). We also included IgD, which is one of the diagnostic markers of
333 HIDS and C-reactive protein (CRP) which is a part of routine laboratory evaluation (although
334 IgD did not show change upon GG and CRP was not among the most increased proteins in
335 HIDS) (**Fig. 4H**). Consistent with proteomic data SAA and MPO showed decrease in patients
336 upon GG supplementation for 1 or 3 months (**Fig. 4I, Fig S4D, E**). PRTN3 dropped in two
337 patients and increased in patient 2. Consistent with plasma proteomics, IgD levels remained
338 unchanged. CRP followed the trend at SAA and showed decrease in patients 1 and 3.
339 Therefore, SAA, MPO, CRP could be potentially utilized as markers of the GG efficacy in HIDS
340 patients, however more data must be collected to validate a robustness of the effect on these
341 markers. Collectively, these findings indicate that GG supplementation has a potential to
342 change the altered plasma protein signature associated with HIDS and provide a starting point
343 for future larger and more targeted studies.

344

345 **Discussion**

346 Clinical symptoms in patients with MKD/HIDS are dominated by immune activation (*for*
347 *recent update, UpToDate2024, [https://www.uptodate.com/contents/hyperimmunoglobulin-d-](https://www.uptodate.com/contents/hyperimmunoglobulin-d-syndrome-clinical-manifestations-and-diagnosis)*
348 *syndrome-clinical-manifestations-and-diagnosis*), manifested as febrile episodes
349 accompanied by other inflammatory symptoms, all of which are typical of autoinflammatory
350 diseases associated with inflammasome activation.

351 Current therapeutic approaches in MKD/HIDS focus on symptomatic management by
352 suppressing inflammation. This includes medications like colchicine, non-steroidal anti-
353 inflammatory drugs (NSAIDs), and cytokine blockade targeting TNF- α and IL-1^{20,21}. However,
354 these options have limited efficacy and long-term sustainability, and do not address the
355 underlying metabolic defect.

356 In this small pilot study, we introduce a novel approach targeting the metabolic basis of
357 MKD/HIDS. This approach investigates the supplementation of metabolites downstream of the
358 enzymatic block with isoprenoid substitute, specifically geranylgeraniol. The strategy aims to
359 bypass the metabolic deficiency and potentially mitigate downstream inflammatory sequelae.

360 No significant changes were observed in the lipid profiles of the patients following GG
361 administration. This aligns with previous reports by Simon et al.²², which demonstrated normal
362 cholesterol levels in MKD/HIDS individuals. Therefore, the lack of alteration in baseline
363 cholesterol and triglyceride levels was unsurprising.

364 As anticipated, the comprehensive analysis of plasma proteins in HIDS patients
365 suggested enhancements in various pathways linked to inflammation and immune signaling.
366 The variability in the protein profiles of HIDS patients correlated with their inflammatory status,
367 as demonstrated by the diminished inflammation in one patient treated with corticosteroids,
368 supported by the expression of acute inflammatory markers such as SAA and CRP (**Fig. 4H,**

369 I). Interestingly, the global protein analysis also detected enrichment in pathways involved in
370 post-translational protein modifications, Rab signaling, and membrane trafficking.
371 Accumulation of unprenylated Rab proteins has been previously detected in cells with
372 decreased MVK activity²³. However the authors showed that while decrease in Rho/Rac/Rap-
373 family GTPases lead to production of IL-1 β in human cells, targeting Rab prenylation had no
374 effect on production of this cytokine, suggesting potentially distinct function of Rab
375 geranylgeranylation. Conversely, the pathways downregulated in HIDS were primarily
376 associated with the regulation of the extracellular matrix. In this regard, previous studies have
377 linked geranylgeraniol supplementation with changes in serum collagen levels in mice²⁴.

378 The proteomic analysis revealed significant alterations in the protein profiles of patients
379 solely upon GG supplementation, without any additional interventions or adjustments to their
380 existing therapy. Significant changes in protein expression (140 proteins) upon the GG can
381 serve as an indicator of the patients' adherence to the treatment. The pathways identified
382 predominantly centered on signaling through small GTPases and membrane trafficking,
383 indicating that GG holds promise as a strategy to modulate these processes in humans.

384 Key finding of our study is that GG supplementation demonstrated the ability to reverse
385 the protein signature in HIDS patients as indicated by proteomics and confirmed by targeted
386 measurements. Among the candidate proteins responsive to GG treatment are numerous key
387 immunoregulatory proteins such as SAA, Ubiquitin-like protein ISG15 (ISG15), Leukocyte
388 immunoglobulin-like receptor subfamily A (LILRA), C-X-C motif chemokine 13 (CXCL13), Ig
389 Kappa chain V-I region HK102- like (IGKV1-5), Myeloperoxidase (MPO), Myeloblastin
390 (PRTN3) and others. We validated expression of MPO and PRTN3 which are connected to
391 neutrophil activation that might have implication in inflammasomopathies^{25,26}. These targets
392 can serve as potential markers for assessing the efficacy of GG supplementation in more
393 targeted studies in future. The IgD levels remained unaffected by the GG supplement
394 supporting the notion that elevated IgD level might not be directly associated with the
395 inflammatory status in HIDS^{12,27}. Although GG treatment induced changes in many HIDS-
396 associated proteins, it did not fully normalize the global plasma profile (**Fig. 4A**). This is likely
397 driven by the strong GG-dependent protein signature that is irrespective of the HIDS status
398 (such as in **Fig. S4A**). In future studies, including healthy group supplemented by GG would
399 help to further determine extent of the effect of GG outside of the inflammatory context of HIDS.
400 Of note, we did not detect changes in classical inflammatory cytokines such as IL-1 β , IL-6 or
401 TNF in plasma proteomics.

402 Despite the observed effectiveness of the GG supplement in altering prenylation-
403 associated pathways, the levels of isoprenoid intermediates (GPP, FPP, GGPP) remained
404 unchanged following GG supplementation at the dosage used (see **Fig. 2**). Geranylgeraniol
405 can be converted endogenously in polyprenol salvage pathway and utilized for protein

406 prenylation^{28,29}. As such, geranylgeraniol is known to reverse defects in protein prenylation in
407 various biological contexts and mitigate secondary effects of several drugs. For example, it is
408 known to reduce statin-induced cytotoxicity through the activity of geranylgeranyl transferases
409 (GGTs)^{30,31}. However, whether geranylgeraniol increases the levels of GGPP has not been
410 conclusively demonstrated to our knowledge. Intriguingly, the enzymatic machinery facilitating
411 this process remains incompletely understood, as only a few enzymes (kinase and phosphate
412 kinase) necessary for conversion of geranylgeraniol to GGPP have been identified in plants
413 and cyanobacteria²⁸. Among other mechanisms, geranylgeraniol can also influence the
414 expression of small GTPases, which may be linked to the plasma signature observed in GG-
415 treated HIDS patients in this study³². Interestingly, it has been shown that endogenous
416 geranylgeraniol production in macrophages contributes to the establishment of endotoxin
417 tolerance³³. Our data suggests that at the given dose, geranylgeraniol does not replenish the
418 levels of GGPP in the circulation, undergoes turnover that precludes the capture of changes
419 in plasma, or acts directly in the form of alcohol. As such, in our study GGPP did not serve as
420 a suitable indicator of the GG supplementation in plasma. However, we assume that the strong
421 significant change in protein expression upon GG detected by proteomics can serve as an
422 indicator of GG activity and as a basis for assessing the GG activity in future studies.

423 A primary limitation of this pilot study investigating GG supplementation in MKD/HIDS
424 patients is the restricted sample size due to the rarity of the disease. Expanding the patient
425 cohort in future studies will require collaborations with other international centers, leveraging
426 international networks and patient registries. Another limitation is the dosage used, which is
427 based on the manufacturer's recommendation in the indication for supplementation with statins
428 therapy. This regimen was selected as safe for the pilot study but is likely inadequate in the
429 absence of isoprenoids in MVK deficiency. In this context, the minimum effective dose
430 administered in a given situation in the mouse model was several times greater¹⁷. Further
431 studies in larger patient cohorts will be required to optimize the dosing scheme. To facilitate
432 such future expansion, the current pilot study aimed to identify simpler and more readily
433 available biomarkers to monitor the therapeutic efficacy of GG substitution beyond complex
434 proteomic profiling. Neutrophil antigens readily assessed using standard ELISA assays were
435 chosen as potential candidates for this purpose.

436

437 **Conclusion**

438 The primary safety objective of the study was successfully met. Aside from the described
439 allergic reaction, which was deemed unrelated to the GG preparation itself, no adverse effects
440 were observed following GG supplementation. The clinical response was modest, with some
441 patients experiencing a slight reduction in the frequency of inflammatory attacks and slightly
442 improved overall feeling and fatigue. While the administered dose and three-month study

443 duration might have been suboptimal, this observed, even if mild, improvement is encouraging.
444 Changes in laboratory parameters provided further evidence for the potential efficacy of GG
445 supplementation in MKD/HIDS. The observed shifts in the proteomic profile towards an anti-
446 inflammatory state suggest that targeting this pathway could offer long-term benefits for
447 disease management. Validation of the dynamics of neutrophil targets as a markers of
448 substitution efficacy holds promise for facilitating larger and international clinical trials to further
449 evaluate this therapeutic strategy in the future.

450

451 **Acknowledgements**

452 We thank the Genome Technology Access Center at the McDonnell Genome Institute at
453 Washington University School of Medicine for help with genomic analysis. The Center is
454 partially supported by NCI Cancer Center Support Grant #P30 CA91842 to the Siteman Cancer
455 Center from the National Center for Research Resources (NCRR), a component of the National
456 Institutes of Health (NIH), and NIH Roadmap for Medical Research. This publication is solely
457 the responsibility of the authors and does not necessarily represent the official view of NCRR
458 or NIH. We thank Andrew J. Martin for help with manuscript corrections.

459

460 **Figure Legends**

461 **Figure 1. Pilot study design.** **A)** Scheme of the mevalonate pathway. **B)** Structures of
462 metabolites and geranylgeraniol (GGOH) as indicated. **C)** Scheme of geranylgeraniol (GG)
463 supplement administration. GG was administered as nutritional supplement for 3 months to
464 patients with HIDS. **D)** Scheme of groups included in the study. **E)** Involved HIDS patient
465 information. NSAIDs, non-steroidal anti-inflammatory drugs. **F)** MVK ribon structure indicating
466 mutations in HIDS patients involved in the study; color coding as in E.

467

468 **Figure 2. GG supplementation does not exert liver toxicity and does not alter lipid and**
469 **isoprenoid plasma composition.** **A)** Assesment of the liver function by measurement of
470 enzyme activity (AST and ALT) and bilirubin levels in serum at indicated times of GG
471 supplementation. **B)** Lipid measurements in plasma in three patients at timepoints post GG
472 supplementation as indicated. **C)** Isoprenoid pyrophosphate levels in plasma analyzed by LC-
473 MS/MS. GPP, geranyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl
474 pyrophosphate. Data in (C) represent mean \pm SEM. *P* values were determined using repeated
475 measure one-way ANOVA with Sidak's test (A, B); and one-way ANOVA with Tuckey's test
476 (C).

477

478 **Figure 3. B lymphocyte analysis.** Cells from PBMCs were analyzed by flow cytometry. Where
479 N = 3, data are mean \pm SEM, *P* values were determined using one-way ANOVA with Tukey's
480 test.

481
482 **Figure 4. GG supplement reverses HIDS-associated protein plasma signature.** **A)** PCA
483 plot of SomaScan plasma proteomics including 7289 targets. Patients 1-3 are indicated in the
484 plot. **B)** Comparison of proteins in 'Healthy' and 'HIDS' groups using limma, proteins were
485 sorted based on *t* statistics. **C)** Pathway analysis of 200 most increased and 200 most
486 decreased proteins in 'HIDS' vs. 'Healthy' compared as in B. Red arrows highlight pathways
487 indicating involvement of GTPase signaling. **D)** Volcano plot of proteomic data comparing
488 'HIDS' vs. 'HIDS + GG'. Significantly different proteins as determined by adjPval (0.05;
489 correction for multiple testing using the Benjamini–Hochberg method) and log fold change (FC)
490 0.5 are shown in red. **E)** Comparison of proteins in 'HIDS' vs. 'HIDS + GG' groups using limma,
491 proteins were sorted based on *t* statistics. **F)** Pathway analysis of 200 most increased and 200
492 most decreased proteins in 'HIDS' vs. 'HIDS + GG' compared as in E. **G)** GSEA statistics
493 comparing HIDS protein signature and effect of GG in HIDS patients (200 most upregulated
494 and 200 most downregulated proteins from 'HIDS' vs. 'HIDS + GG' were used). **H)** 20 most
495 upregulated proteins from comparison between 'Healthy' and 'HIDS' including only samples
496 from patients P1 and P3. IgD expression is shown separately. Red arrows indicate targets
497 chosen for *in vitro* validation. **I)** Targeted detection of proteins in plasma or serum of HIDS
498 patients at indicated time of treatment with GG.

499
500 **Figure S1.** Isoprenoid pyrophosphate levels in plasma analyzed by LC-MS/MS. GPP, geranyl
501 pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate. Data
502 are presented as paired values from patients before and after 3 months of GG treatment. *P*
503 values were determined Wilcoxon matched-pairs signed rank test.

504
505 **Figure S2.** Gating strategy used to identify and resolve B cell populations from PBMCs.

506
507 **Figure S3.** **A)** Volcano plot of proteomic data comparing 'Healthy' vs. 'HIDS' groups. **B)**
508 Comparison of proteins in 'Healthy' and 'HIDS' ranked by limma statistics showing 10 most
509 'up' and 10 most 'down' proteins detected in HIDS. Individual patients before and after GG
510 treatment are labeled by color coding. **C)** GSEA statistics comparing ranked by limma 'Healthy'
511 vs. 'HIDS' protein signature and selected pathways from Fig. 4C. **D)** Volcano plot of proteomic
512 data comparing 'Healthy' vs. 'Statin' groups. Significantly differential proteins as determined by
513 adjPval (0.05) and log fold change (FC) 0.5 are shown in red. **E)** Pathway analysis of 200

514 most increased and 200 most decreased proteins in 'Healthy' vs. 'Statin' compared by limma
515 statistics.

516

517 **Figure S4. A)** Example of SomaScan expression data of proteins significantly upregulated by
518 GG in HIDS patients across all experimental groups. **B)** Proteins most increased in 'Healthy'
519 vs. 'HIDS' ranked by limma statistics. Samples from individual patients are labeled by color
520 coding. **C)** GSEA statistics comparing GG protein signature and 200 most increased and 200
521 most decreased proteins in 'HIDS' compared to 'Healthy'. **D)** SomaScan data on expression
522 of proteins as indicated. **E)** Protein detection in plasma measured by ELISA. Boxplot in (A) and
523 (D) represent mean/min and max values from N = 3. Adjusted P values in SomaScan data (A)
524 and (D) were determined using the limma package comparing 'HIDS' and 'HIDS + GG', and
525 correction for multiple testing using the Benjamini–Hochberg method.

526 **References:**

- 527 (1) Drenth, J. P.; Cuisset, L.; Grateau, G.; Vasseur, C.; van de Velde-Visser, S. D.; de
528 Jong, J. G.; Beckmann, J. S.; van der Meer, J. W.; Delpech, M. Mutations in the Gene
529 Encoding Mevalonate Kinase Cause Hyper-IgD and Periodic Fever Syndrome.
530 International Hyper-IgD Study Group. *Nat. Genet.* **1999**, *22* (2), 178–181.
531 <https://doi.org/10.1038/9696>.
- 532 (2) van der Burgh, R.; Ter Haar, N. M.; Boes, M. L.; Frenkel, J. Mevalonate Kinase
533 Deficiency, a Metabolic Autoinflammatory Disease. *Clin. Immunol.* **2013**, *147* (3), 197–
534 206. <https://doi.org/10.1016/j.clim.2012.09.011>.
- 535 (3) Wang, M.; Casey, P. J. Protein Prenylation: Unique Fats Make Their Mark on Biology.
536 *Nat. Rev. Mol. Cell Biol.* **2016**, *17* (2), 110–122. <https://doi.org/10.1038/nrm.2015.11>.
- 537 (4) Munoz, M. A.; Jurczyk, J.; Simon, A.; Hissaria, P.; Arts, R. J. W.; Coman, D.; Boros,
538 C.; Mehr, S.; Rogers, M. J. Defective Protein Prenylation in a Spectrum of Patients
539 With Mevalonate Kinase Deficiency. *Front. Immunol.* **2019**, *10*.
- 540 (5) Masumoto, J.; Zhou, W.; Morikawa, S.; Hosokawa, S.; Taguchi, H.; Yamamoto, T.;
541 Kurata, M.; Kaneko, N. Molecular Biology of Autoinflammatory Diseases. *Inflamm.*
542 *Regen.* **2021**, *41* (1), 33. <https://doi.org/10.1186/s41232-021-00181-8>.
- 543 (6) Park, Y. H.; Wood, G.; Kastner, D. L.; Chae, J. J. Pyrin Inflammasome Activation and
544 RhoA Signaling in the Autoinflammatory Diseases FMF and HIDS. *Nat. Immunol.*
545 **2016**, *17* (8), 914–921. <https://doi.org/10.1038/ni.3457>.
- 546 (7) Akula, M. K.; Shi, M.; Jiang, Z.; Foster, C. E.; Miao, D.; Li, A. S.; Zhang, X.; Gavin, R.
547 M.; Forde, S. D.; Germain, G.; Carpenter, S.; Rosadini, C. V.; Gritsman, K.; Chae, J. J.;
548 Hampton, R.; Silverman, N.; Gravallesse, E. M.; Kagan, J. C.; Fitzgerald, K. A.;
549 Kastner, D. L.; Golenbock, D. T.; Bergo, M. O.; Wang, D. Control of the Innate
550 Immune Response by the Mevalonate Pathway. *Nat. Immunol.* **2016**, *17* (8), 922–929.
551 <https://doi.org/10.1038/ni.3487>.
- 552 (8) Skinner, O. P.; Jurczyk, J.; Baker, P. J.; Masters, S. L.; Rios Wilks, A. G.;
553 Clearwater, M. S.; Robertson, A. A. B.; Schroder, K.; Mehr, S.; Munoz, M. A.; Rogers,
554 M. J. Lack of Protein Prenylation Promotes NLRP3 Inflammasome Assembly in
555 Human Monocytes. *J. Allergy Clin. Immunol.* **2019**, *143* (6), 2315–2317.e3.
556 <https://doi.org/https://doi.org/10.1016/j.jaci.2019.02.013>.
- 557 (9) Bekkering, S.; Arts, R. J. W.; Novakovic, B.; Kourtzelis, I.; van der Heijden, C. D. C.
558 C.; Li, Y.; Popa, C. D.; Ter Horst, R.; van Tuijl, J.; Netea-Maier, R. T.; van de

- 559 Veerdonk, F. L.; Chavakis, T.; Joosten, L. A. B.; van der Meer, J. W. M.; Stunnenberg,
560 H.; Riksen, N. P.; Netea, M. G. Metabolic Induction of Trained Immunity through the
561 Mevalonate Pathway. *Cell* **2018**, *172* (1–2), 135-146.e9.
562 <https://doi.org/10.1016/j.cell.2017.11.025>.
- 563 (10) Bibby, J. A.; Purvis, H. A.; Hayday, T.; Chandra, A.; Okkenhaug, K.; Rosenzweig, S.;
564 Aksentijevich, I.; Wood, M.; Lachmann, H. J.; Kemper, C.; Cope, A. P.; Perucha, E.
565 Cholesterol Metabolism Drives Regulatory B Cell IL-10 through Provision of
566 Geranylgeranyl Pyrophosphate. *Nat. Commun.* **2020**, *11* (1), 3412.
567 <https://doi.org/10.1038/s41467-020-17179-4>.
- 568 (11) Du, X.; Zeng, H.; Liu, S.; Guy, C.; Dhungana, Y.; Neale, G.; Bergo, M. O.; Chi, H.
569 Mevalonate Metabolism–Dependent Protein Geranylgeranylation Regulates
570 Thymocyte Egress. *J. Exp. Med.* **2019**, *217* (2), e20190969.
571 <https://doi.org/10.1084/jem.20190969>.
- 572 (12) Ammouri, W.; Cuisset, L.; Rouaghe, S.; Rolland, M.-O.; Delpech, M.; Grateau, G.;
573 Ravet, N. Diagnostic Value of Serum Immunoglobulinaemia D Level in Patients with a
574 Clinical Suspicion of Hyper IgD Syndrome. *Rheumatology (Oxford)*. **2007**, *46* (10),
575 1597–1600. <https://doi.org/10.1093/rheumatology/kem200>.
- 576 (13) Maity, P. C.; Blount, A.; Jumaa, H.; Ronneberger, O.; Lillemeier, B. F.; Reth, M. B Cell
577 Antigen Receptors of the IgM and IgD Classes Are Clustered in Different Protein
578 Islands That Are Altered during B Cell Activation. *Sci. Signal.* **2015**, *8* (394), ra93.
579 <https://doi.org/10.1126/scisignal.2005887>.
- 580 (14) Silva, R. C. M. C. Hyper-IgD Syndrome: Caused by Deficiency on Ras Prenylation and
581 Trained Immunity? *J. Clin. Immunol.* **2023**. [https://doi.org/10.1007/s10875-023-01548-](https://doi.org/10.1007/s10875-023-01548-x)
582 [x](https://doi.org/10.1007/s10875-023-01548-x).
- 583 (15) Morgan, M. A.; Sebil, T.; Aydilek, E.; Peest, D.; Ganser, A.; Reuter, C. W. M.
584 Combining Prenylation Inhibitors Causes Synergistic Cytotoxicity, Apoptosis and
585 Disruption of RAS-to-MAP Kinase Signalling in Multiple Myeloma Cells. *Br. J.*
586 *Haematol.* **2005**, *130* (6), 912–925. <https://doi.org/10.1111/j.1365-2141.2005.05696.x>.
- 587 (16) Munoz, M. A.; Skinner, O. P.; Masle-Farquhar, E.; Jurczyk, J.; Xiao, Y.; Fletcher, E.
588 K.; Kristianto, E.; Hodson, M. P.; O'Donoghue, S. I.; Kaur, S.; Brink, R.; Zahra, D. G.;
589 Deenick, E. K.; Perry, K. A.; Robertson, A. A.; Mehr, S.; Hissaria, P.; Mulders-
590 Manders, C. M.; Simon, A.; Rogers, M. J. Increased Core Body Temperature
591 Exacerbates Defective Protein Prenylation in Mouse Models of Mevalonate Kinase
592 Deficiency. *J. Clin. Invest.* **2022**, *132* (19). <https://doi.org/10.1172/JCI160929>.

- 593 (17) Marcuzzi, A.; Pontillo, A.; De Leo, L.; Tommasini, A.; Decorti, G.; Not, T.; Ventura, A.
594 Natural Isoprenoids Are Able to Reduce Inflammation in a Mouse Model of
595 Mevalonate Kinase Deficiency. *Pediatr. Res.* **2008**, *64* (2), 177–182.
596 <https://doi.org/10.1203/PDR.0b013e3181761870>.
- 597 (18) Gold, L.; Ayers, D.; Bertino, J.; Bock, C.; Bock, A.; Brody, E. N.; Carter, J.; Dalby, A.
598 B.; Eaton, B. E.; Fitzwater, T.; Flather, D.; Forbes, A.; Foreman, T.; Fowler, C.;
599 Gawande, B.; Goss, M.; Gunn, M.; Gupta, S.; Halladay, D.; Heil, J.; Heilig, J.; Hicke,
600 B.; Husar, G.; Janjic, N.; Jarvis, T.; Jennings, S.; Katilius, E.; Keeney, T. R.; Kim, N.;
601 Koch, T. H.; Kraemer, S.; Kroiss, L.; Le, N.; Levine, D.; Lindsey, W.; Lollo, B.;
602 Mayfield, W.; Mehan, M.; Mehler, R.; Nelson, S. K.; Nelson, M.; Nieuwlandt, D.;
603 Nikrad, M.; Ochsner, U.; Ostroff, R. M.; Otis, M.; Parker, T.; Pietrasiewicz, S.;
604 Resnicow, D. I.; Rohloff, J.; Sanders, G.; Sattin, S.; Schneider, D.; Singer, B.; Stanton,
605 M.; Sterkel, A.; Stewart, A.; Stratford, S.; Vaught, J. D.; Vrkljan, M.; Walker, J. J.;
606 Watrobka, M.; Waugh, S.; Weiss, A.; Wilcox, S. K.; Wolfson, A.; Wolk, S. K.; Zhang,
607 C.; Zichi, D. Aptamer-Based Multiplexed Proteomic Technology for Biomarker
608 Discovery. *PLoS One* **2010**, *5* (12), e15004.
609 <https://doi.org/10.1371/journal.pone.0015004>.
- 610 (19) Kleverov, M.; Zenkova, D.; Kamenev, V.; Sablina, M.; Artyomov, M. N.; Sergushichev,
611 A. A. Phantassus: Web-Application for Visual and Interactive Gene Expression
612 Analysis. *bioRxiv* **2022**, 2022.12.10.519861.
613 <https://doi.org/10.1101/2022.12.10.519861>.
- 614 (20) Politiek, F. A.; Waterham, H. R. Compromised Protein Prenylation as Pathogenic
615 Mechanism in Mevalonate Kinase Deficiency. *Front. Immunol.* **2021**, *12*, 724991.
616 <https://doi.org/10.3389/fimmu.2021.724991>.
- 617 (21) Favier, L. A.; Schulert, G. S. Mevalonate Kinase Deficiency: Current Perspectives.
618 *Appl. Clin. Genet.* **2016**, *9*, 101–110. <https://doi.org/10.2147/TACG.S93933>.
- 619 (22) Simon, A.; Bijzet, J.; Voorbij, H. A. M.; Mantovani, A.; van der Meer, J. W. M.; Drenth,
620 J. P. H. Effect of Inflammatory Attacks in the Classical Type Hyper-IgD Syndrome on
621 Immunoglobulin D, Cholesterol and Parameters of the Acute Phase Response. *J.*
622 *Intern. Med.* **2004**, *256* (3), 247–253. [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-2796.2004.01359.x)
623 [2796.2004.01359.x](https://doi.org/10.1111/j.1365-2796.2004.01359.x).
- 624 (23) Jurczykuk, J.; Munoz, M. A.; Skinner, O. P.; Chai, R. C.; Ali, N.; Palendira, U.; Quinn, J.
625 M. W.; Preston, A.; Tangye, S. G.; Brown, A. J.; Argent, E.; Ziegler, J. B.; Mehr, S.;
626 Rogers, M. J. Mevalonate Kinase Deficiency Leads to Decreased Prenylation of Rab

- 627 GTPases. *Immunol. Cell Biol.* **2016**, *94* (10), 994–999.
628 [https://doi.org/https://doi.org/10.1038/icb.2016.58](https://doi.org/10.1038/icb.2016.58).
- 629 (24) Chung, E.; Elmassry, M. M.; Cao, J. J.; Kaur, G.; Dufour, J. M.; Hamood, A. N.; Shen,
630 C.-L. Beneficial Effect of Dietary Geranylgeraniol on Glucose Homeostasis and Bone
631 Microstructure in Obese Mice Is Associated with Suppression of Proinflammation and
632 Modification of Gut Microbiome. *Nutr. Res.* **2021**, *93*, 27–37.
633 <https://doi.org/10.1016/j.nutres.2021.07.001>.
- 634 (25) Martirosyan, A.; Poghosyan, D.; Ghonyan, S.; Mkrtchyan, N.; Amaryan, G.; Manukyan,
635 G. Transmigration of Neutrophils From Patients With Familial Mediterranean Fever
636 Causes Increased Cell Activation. *Front. Immunol.* **2021**, *12*, 672728.
637 <https://doi.org/10.3389/fimmu.2021.672728>.
- 638 (26) Apostolidou, E.; Skendros, P.; Kambas, K.; Mitroulis, I.; Konstantinidis, T.;
639 Chrysanthopoulou, A.; Nakos, K.; Tsironidou, V.; Koffa, M.; Boumpas, D. T.; Ritis, K.
640 Neutrophil Extracellular Traps Regulate IL-1 β -Mediated Inflammation in Familial
641 Mediterranean Fever. *Ann. Rheum. Dis.* **2016**, *75* (1), 269–277.
642 <https://doi.org/10.1136/annrheumdis-2014-205958>.
- 643 (27) van der Hilst, J. C. H.; Bodar, E. J.; Barron, K. S.; Frenkel, J.; Drenth, J. P. H.; van der
644 Meer, J. W. M.; Simon, A. Long-Term Follow-up, Clinical Features, and Quality of Life
645 in a Series of 103 Patients with Hyperimmunoglobulinemia D Syndrome. *Medicine*
646 (*Baltimore*). **2008**, *87* (6), 301–310. <https://doi.org/10.1097/MD.0b013e318190cfb7>.
- 647 (28) Verdaguer, I. B.; Crispim, M.; Hernández, A.; Katzin, A. M. The Biomedical Importance
648 of the Missing Pathway for Farnesol and Geranylgeraniol Salvage. *Molecules* **2022**,
649 *27* (24). <https://doi.org/10.3390/molecules27248691>.
- 650 (29) Bentinger, M.; Grünler, J.; Peterson, E.; Swiezewska, E.; Dallner, G. Phosphorylation
651 of Farnesol in Rat Liver Microsomes: Properties of Farnesol Kinase and Farnesyl
652 Phosphate Kinase. *Arch. Biochem. Biophys.* **1998**, *353* (2), 191–198.
653 <https://doi.org/10.1006/abbi.1998.0611>.
- 654 (30) Jaśkiewicz, A.; Pająk, B.; Litwiniuk, A.; Urbańska, K.; Orzechowski, A. Geranylgeraniol
655 Prevents Statin-Dependent Myotoxicity in C2C12 Muscle Cells through RAP1
656 GTPase Prenylation and Cytoprotective Autophagy. *Oxid. Med. Cell. Longev.* **2018**,
657 *2018*, 6463807. <https://doi.org/10.1155/2018/6463807>.
- 658 (31) Balaz, M.; Becker, A. S.; Balazova, L.; Straub, L.; Müller, J.; Gashi, G.; Maushart, C. I.;
659 Sun, W.; Dong, H.; Moser, C.; Horvath, C.; Efthymiou, V.; Rachamin, Y.; Modica, S.;

- 660 Zellweger, C.; Bacanovic, S.; Stefanicka, P.; Varga, L.; Ukropcova, B.; Profant, M.;
661 Opitz, L.; Amri, E.-Z.; Akula, M. K.; Bergo, M.; Ukropec, J.; Falk, C.; Zamboni, N.;
662 Betz, M. J.; Burger, I. A.; Wolfrum, C. Inhibition of Mevalonate Pathway Prevents
663 Adipocyte Browning in Mice and Men by Affecting Protein Prenylation. *Cell Metab.*
664 **2019**, 29 (4), 901-916.e8. <https://doi.org/10.1016/j.cmet.2018.11.017>.
- 665 (32) Fliefel, R. M.; Entekhabi, S. A.; Ehrenfeld, M.; Otto, S. Geranylgeraniol (GGOH) as a
666 Mevalonate Pathway Activator in the Rescue of Bone Cells Treated with Zoledronic
667 Acid: An In Vitro Study. *Stem Cells Int.* **2019**, 2019, 4351327.
668 <https://doi.org/10.1155/2019/4351327>.
- 669 (33) Kim, J.; Lee, J. N.; Ye, J.; Hao, R.; Debose-Boyd, R.; Ye, J. Sufficient Production of
670 Geranylgeraniol Is Required to Maintain Endotoxin Tolerance in Macrophages. *J.*
671 *Lipid Res.* **2013**, 54 (12), 3430–3437. <https://doi.org/10.1194/jlr.M042549>.

Figure 1




Figure 1. Pilot study design. **A)** Scheme of the mevalonate pathway. **B)** Structures of metabolites and geranylgeraniol (GGOH) as indicated. **C)** Scheme of geranylgeraniol supplement (GG Pure-Geranylgeraniol, Xtend-life; GG) administration. GG was administered as nutritional supplement for 3 months to patients with HIDS. **D)** Scheme of groups included in the study. **E)** Involved HIDS patient information. NSAIDs, non-steroidal anti-inflammatory drugs. **F)** MVK ribbon structure indicating mutations in HIDS patients involved in the study; color coding as in E.

Figure 2




Figure 2. GG supplementation does not exert liver toxicity and does not alter lipid and isoprenoid plasma composition. **A)** Assessment of the liver function by measurement of enzyme activity (AST and ALT) and bilirubin levels in serum at indicated times of GG supplementation. **B)** Lipid measurements in plasma in three patients at timepoints post GG supplementation as indicated. **C)** Isoprenoid pyrophosphate levels in plasma analyzed by LC-MS/MS. GPP, geranyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate. Data in (C) represent mean \pm SEM. *P* values were determined using repeated measure one-way ANOVA with Holm-Sidak's test (A, B); and one-way ANOVA with Tuckey's test (C).

Figure 3




Figure 3. B lymphocyte analysis. Cells from PBMCs were analyzed by flow cytometry. Where N = 3, data are mean \pm SEM, *P* values were determined using one-way ANOVA with Tukey's test.

Figure 4




Figure 4. GG supplement reverses HIDS-associated protein plasma signature. **A)** PCA plot of SomaScan plasma proteomics including 7289 targets. Patients 1-3 are indicated in the plot. **B)** Comparison of proteins in 'Healthy' and 'HIDS' groups using limma, proteins were sorted based on t statistics. **C)** Pathway analysis of 200 most increased and 200 most decreased proteins in 'HIDS' vs. 'Healthy' compared as in B. Red arrows highlight pathways indicating involvement of GTPase signaling. **D)** Volcano plot of proteomic data comparing 'HIDS' vs. 'HIDS + GG'. Significantly different proteins as determined by adjPval (0.05; correction for multiple testing using the Benjamini-Hochberg method) and log fold change (FC) 0.5 are shown in red. **E)** Comparison of proteins in 'HIDS' vs. 'HIDS + GG' groups using limma, proteins were sorted based on t statistics. **F)** Pathway analysis of 200 most increased and 200 most decreased proteins in 'HIDS' vs. 'HIDS + GG' compared as in E. **G)** GSEA statistics comparing HIDS protein signature and effect of GG in HIDS patients (200 most upregulated and 200 most downregulated proteins from 'HIDS' vs. 'HIDS + GG' were used). **H)** 20 most upregulated proteins from comparison between 'Healthy' and 'HIDS' including only samples from patients P1 and P3. IgD expression is shown separately. Red arrows indicate targets chosen for validation by targeted measurements. **I)** Targeted detection of proteins in plasma or serum of HIDS patients at indicated time of treatment with GG.

Figure S1




Figure S1. Isoprenoid pyrophosphate levels in plasma analyzed by LC-MS/MS. GPP, geranyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate. Data are presented as paired values from patients before and after 3 months of GG treatment. *P* values were determined using Wilcoxon matched-pairs signed rank test.

Figure S2




Figure S2. Gating strategy used to identify and resolve B cell populations from PBMCs.

Figure S3




Figure S3. A) Volcano plot of proteomic data comparing 'Healthy' vs. 'HIDS' groups. **B)** Comparison of proteins in 'Healthy' and 'HIDS' ranked by limma statistics showing 10 most 'up' and 10 most 'down' proteins detected in HIDS. Individual patients before and after GG treatment are labeled by color coding. **C)** GSEA statistics comparing ranked by limma 'Healthy' vs. 'HIDS' protein signature and selected pathways from Fig. 4C. **D)** Volcano plot of proteomic data comparing 'Healthy' vs. 'Statin' groups. Significantly differential proteins as determined by adjPval and log fold change (FC) 0.5 are shown in red. **E)** Pathway analysis of 200 most increased and 200 most decreased proteins in 'Healthy' vs. 'Statin' compared by limma statistics.

Figure S4




Figure S4. A) Example of SomaScan expression data of proteins significantly upregulated by GG in HIDS patients across all experimental groups. **B)** Proteins most increased in 'Healthy' vs. 'HIDS' ranked by limma statistics. Samples from individual patients are labeled by color coding. **C)** GSEA statistics comparing GG protein signature and 200 most increased and 200 most decreased proteins in 'HIDS' compared to 'Healthy'. **D)** SomaScan data on expression of proteins as indicated. **E)** Protein detection in plasma measured by ELISA. Boxplot in (A) and (D) represent mean/min and max values from N = 3. Adjusted *P* values in SomaScan data (A) and (D) were determined using the limma package comparing 'HIDS' and 'HIDS + GG', and correction for multiple testing using the Benjamini–Hochberg method.